The sampling frame in this study (non-adherence over the prior one-year period) reduces the risk of this occurrence, although it remains a very definite, unquantifiable limitation on the interpretation of our results.
Age and polypharmacy were independent predictors of treatment duration and discontinuation prior to one year.
This finding deserves additional exploration, which could be performed by obtaining serum samples for persistence evaluation prior to one year post-vaccination in a future study.
In both the monotherapy and polypharmacy cohorts, patients younger than 25 years had a higher frequency of treatment discontinuation prior to one year than those 26 years and older.
CoC patients were significantly more likely to report noise after a year compared with controls (p < 0.01) (Fig. 4) whereas the timing of noise commencing prior to one year following surgery was similar in both groups.
Prior to one year before diagnosis of breast cancer, about 20% of cases and controls had used tricyclic antidepressants (adjusted odds ratio=1.06, 95% CI 0.94 1.19) and 6% of each group had used selective serotonin reuptake inhibitors (OR=0.98, 95% CI 0.80 1.18).
A proportion of the animals in our cohort either developed masses much later than 16 weeks post-induction or had no palpable masses prior to one year post-induction.
Data were analyzed in a retrospective manner 1 year prior and prospectively one year after the initiation of EPO.
Glycosylated hemoglobin (HbA1c) and obesity measures were collected prior to and one year after full project implementation.
As discussed in Razzaghi et al.[ 50], for cases density was reported from the screening or diagnostic mammogram performed within five years prior to or one year after breast cancer diagnosis.
A total of 491 cases had mammograms within five years prior to and one year after diagnosis and 528 controls had screening or diagnostic mammograms close to the dates of selection into CBCS.
